CAR-T治疗失败后DLBCL的下一步治疗选择
After CAR-T Failure in Diffuse Large B-Cell Lymphoma, What Comes Next?
研究显示,bispecific抗体在CAR-T失败后的DLBCL患者中表现出较高完全缓解率,但早期复发患者效果有限。EPCORE DLBCL-2研究显示,固定疗程的epcoritamab联合R-CHOP方案显著降低疾病进展或死亡风险,可能改变一线治疗标准。
介绍了CAR-T失败后的治疗选择,特别是bispecific抗体的疗效和前景。
— Bispecific antibodies have become the go-to option
November 11, 2026 • 4 min read
CD19-targeted chimeric antigen receptor (CAR) T-cells have emerged as a second- and later-line treatment strategy for patients with diffuse large B-cell lymphoma (DLBCL), with three FDA-approved products.
"Across CAR T-cell products in patients with large B-cell lymphoma, we see durable, ongoing responses in about 30% to 40% of patients," Alex Herrera, MD, of City of Hope Comprehensive Cancer Center in Duarte, California, told MedPage Today.
A recent landmark trial found that 12 of 38 patients -- half with heavily pretreated large B-cell lymphoma -- remained lymphoma-free 10 years after receiving a single dose of CD19-targeted CAR T-cell therapy.
However, "a majority of patients ultimately do not achieve long-term remission with CAR-T," Herrera observed.
For example, 55 of 116 people with aggressive B-cell lymphomas in a cohort study had treatment failure, with about half of those patients relapsing within 8 months of receiving CAR T-cell therapy.
"CAR T-cell therapy has offered hope to a lot of patients, but has created a whole new unmet need," said Lorenzo Falchi, MD, of Memorial Sloan Kettering Cancer Center in New York City. "What happens for that majority of patients in relapse?"
As for what might come next, he noted that chemotherapy would have been first- and second-line options for DLBCL in the past, and patients might have received several different types.
"Now, where you have CAR T-cell therapy, patients might in the third line have seen only one line of chemotherapy," Falchi told MedPage Today. "So, there is space for chemotherapy as a salvage option."
Bispecific Antibodies
That said, the most likely option would be a bispecific antibody targeting CD20 and CD3. Epcoritamab (Epkinly) and glofitamab (Columvi) have received FDA approval for relapsed/refractory DLBCL after two or more lines of therapy, and have "become a standard in that post-CAR-T space," Herrera said.
These drugs have transformative potential for several reasons, Falchi noted. "Most important is that in patients who experience the failure of CAR T-cell therapy, as many as 35% to 40% can achieve a complete response with bispecific antibodies used alone," he said. "That is not achieved with anything else in that space, including chemotherapy."
In a phase I/II study, 35% of 52 patients with relapsed or refractory DLBCL who had previously received CAR T-cell therapy achieved a complete response with glofitamab monotherapy. "And we know now with longer-term follow-up that among the patients who respond, a good majority remain in response in the long term," Falchi added.
However, even with a promising therapy like a bispecific antibody, efficacy is likely limited in patients who had early relapse or progression on CAR T-cell therapy.
"If a patient never responds or has a very rapid progression right after CAR T-cell therapy, that in and of itself is associated with a poor prognosis," Herrera pointed out. "That's just logical, right? The therapy really didn't work, and kinetically the disease is progressing very rapidly. We know that those patients are less likely to respond to whatever we give them next."
In a retrospective analysis of patients with large B-cell lymphoma who experienced relapse after CD19-directed CAR T-cell therapy, those receiving bispecific antibodies during early relapse (≤3 months) achieved a significantly worse outcome, with an overall response rate (ORR) of 29% and progression-free survival (PFS) of 2.2 months, compared with patients with an intermediate (4-6 months; ORR 54%, PFS 3.7 months) or late relapse (>6 months; ORR 60%, PFS 10.5 months).
Antibody-drug conjugates such as polatuzumab vedotin (Polivy) and loncastuximab tesirine (Zynlonta) provide another option after progression on CAR T-cell therapy.
A "cutting-edge" approach is to combine them with bispecific antibodies, Falchi said. "That's where we're seeing some of the highest response rates and some of the more tolerable safety profiles."
For example, in a phase Ib/II trial of glofitamab plus polatuzumab vedotin, the ORR was 78.3%, with a complete response rate of 59.7%, among patients with relapsed/refractory large B-cell lymphoma, including patients with previous CAR T-cell therapy failure.
A Changing Conversation?
Several studies being presented at the upcoming American Society of Hematology (ASH) annual meeting will address relapsed/refractory DLBCL, including patients who received prior CAR T-cell therapy.
Initial results from a study evaluating venetoclax (Venclexta), ibrutinib (Imbruvica), prednisone, obinutuzumab (Gazyva), and lenalidomide (Revlimid) in patients with relapsed/refractory DLBCL, including 20 patients with prior CAR T-cell therapy, showed the regimen achieved an ORR of 54%, with 38% of patients achieving a complete response.
In long-term results being presented at ASH, 65% of all responses and 78% of complete responses were ongoing at 5 years.
Falchi also pointed out that recently released results from the phase III EPCORE DLBCL-2 trial had a "very strong potential to change the standard of care" for frontline therapy.
In this study of newly diagnosed patients with DLBCL, fixed-duration epcoritamab in combination with standard-of-care rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reduced the risk of disease progression or death by 51% compared with R-CHOP alone (HR 0.49, 95% CI 0.36-0.67, P<0.0001), "which is kind of unprecedented, really, in the frontline space," Falchi noted, adding that the study is "almost certainly going to change practice."
"And what that will do is move many of the patients who would have gotten bispecifics in the third line into the front line, and that will create another new unmet need because now you've used them in the front line," he said.
Falchi added that he and his colleagues are waiting for readouts on a half-dozen or so randomized trials, "and we're going to find ourselves with an embarrassment of riches."
"We're going to have maybe five or six positive frontline trials, and all of these trials are using some of the [therapies] that we're using now in the third or fourth line," he said. "So I truly think that this conversation will completely change in the next year or two."
来源:MedPage Today · medpagetoday.com